Arya AK, Sethuraman K, Waddell J, Cha YS, Liang Y, Bhopale VM, Bhat AR, Imtiyaz Z, Dakessian A, Lee Y, Thom SR. Science Advances. 2025 Feb 7;11(6):eado9751. doi: 10.1126/sciadv.ado9751. Epub 2025 Feb 7. PMID: 39919185; PMCID: PMC11804920.
Lee J, Sasaki F, Koike E, Cho M, Lee Y, Dho SH, Lee J, Lee E, Toyohara E, Sunakawa M, Ishibashi M, Hung HH, Nishioka S, Komine R, Okura C, Shimizu M, Ikawa M, Yoshimura A, Morita R, Kim LK. Cell Death Differ. 2024 Dec;31(12):1679-1694. doi: 10.1038/s41418-024-01367-6. Epub 2024 Aug 24. PMID: 39179640; PMCID: PMC11618363.
Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens. Endogenous levels plummet in ARDS, correlating with disease severity. NORTH BRUNSWICK, N.J., October 17, 2024 (GLOBE NEWSWIRE) — BioAegis Therapeutics,
NORTH BRUNSWICK, N.J., September 12, 2024 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that its Co-founder, Steve Cordovano, will present at the upcoming MedInvest Biotech & Pharma Investor Conference in New York City on September 18 and 19. The presentation, “Conquering Diseases Driven
BioAegis CEO and co-founder, Susan Levinson, PhD, will be participating in the upcoming 6th Annual Inflammasome Therapeutics Summit in Boston, MA.
September 10-12, 2024: 6th Annual Inflammasome Therapeutics Summit Read More »
BioAegis co-founder, Steve Cordovano, was invited to present at the upcoming MedInvest Biotech & Pharma Investor Conference in New York City. The presentation, “Conquering Disease Driven by Excess Inflammation” will highlight BioAegis’ novel, host-directed immune regulator protein. The presentation will also discuss BioAegis’ lead indication, Acute Respiratory Distress Syndrome (ARDS), and its phase 2 global
September 18-19, 2024: MedInvest Biotech & Pharma Investor Conference Read More »
Large phase 2 global study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., February 27, 2024 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, is pleased to announce site recruitment for BTI-203, a Phase 2 study
Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., October 16, 2023 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, is pleased to announce a second partnership
BioAegis sponsored webinar, Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases will delve beneath the surface of this rapidly growing field of auto-inflammatory and hyper-inflammatory diseases. It will explore what we know and will need to know moving forward, in particular: How these diseases of the innate immune
Webinar will take place Tuesday, May 23, 2023 at 2:00 PM Eastern Time NORTH BRUNSWICK, N.J., May 10, 2023 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage company developing novel therapies for inflammatory diseases through a portfolio built around plasma gelsolin (pGSN), a highly conserved and abundant endogenous human immune regulatory protein, announces that it